trial · primary record
TGX-007
Glioblastoma (GBM)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 68 |
| Primary completion | 2033-09 |
| Primary endpoint | Safety and tolerability of TGX-007 when administered to patients with newly diagnosed HGG or recurrent GBM and to identify the OBD |
| Registry ID | NCT07346144 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:37.728Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07346144
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.